"Twincretin" tirzepatide-treated participants in SURMOUNT-5 lost a mean 50 lbs vs an average loss of 33 lbs for those treated with semaglutide.
In a study of adults enrolled in a telehealth weight management program, 45% decreased their alcohol use after taking antiobesity medication.
With the recent surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.
Michael Crotty, MD, provides practical guidance for on integrating GLP-1 receptor agonists into a comprehensive obesity treatment plan.
Obesity medicine specialist Michael Crotty, MD, discusses the benefits of GLP-1 receptor agonist use in weight management and its impact on obesity-related comorbidities.
The proposal would expand antiobesity drug access for more than 7 million people with Medicare and Medicaid coverage.
The investigational weight loss drug showed substantial weight loss among people with obesity or overweight with or without T2D without plateaus.
Michael Crotty, MD, an expert in obesity medicine, discusses GLP-1RAs in the context of weight loss, including the novel dual agonist survodutide.
Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.
Your daily dose of the clinical news you may have missed.